Global Trial Expansion Ichor's expansion into Australia, Europe, and the UK along with the launch of Ichor Clinical Trial Services positions the company as a go-to partner for multi-region trial execution. Target biotech and pharma clients seeking international site identification, recruitment, and regulatory-compliant trial management to accelerate global programs.

Longevity Focus Advantage As a longevity-centered CRO and end-to-end drug development platform with four preclinical candidates in its portfolio, Ichor offers a differentiated value proposition for aging and age-related disease programs. Cross-sell discovery, pharmacology, protocol design, and biomarker strategies tailored to longevity endpoints.

Trial Leadership Growth The appointment of Lisa Sonneborn to lead the new trial services unit signals a strategic emphasis on scalable, execution-focused trials. Leverage this to engage sponsors needing robust operations, site qualification, recruitment, and protocol execution across diverse geographies.

Academic Collaboration Clarkson University partnership and regional biotech cluster initiatives create opportunities to serve university-affiliated startups and spinouts with preclinical CRO, translational services, and grant-driven collaborations. Position Ichor as the partner for academia-to-industry technology transfer and early clinical readiness.

Tech Partnership Ongoing SPR chip technology development and investments in biotech tools signal open doors for clients requiring advanced assay platforms, binding kinetics measurement, and sensor-based screening. Propose co-development, licensing, or pilot collaborations with pharma/biotech clients leveraging this capability.